 |
|
Treatment of Ocular Myasthenia With Corticosteroids
Yes
Mark A. Agius, MD, FRCP (C, Glasg)
From the Department of Neurology, University of California, Davis.
Arch Neurol. 2000;57:750-751.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
OCULAR findings often represent the first, and sometimes the sole manifestation of acquired MG.1-2 Ocular MG, with weakness restricted to the ocular muscles, is generally considered a mild subtype of MG. Nonetheless, the diagnosis and management of purely ocular MG may be particularly challenging and frustrating.3 Diplopia and ptosis, resulting from dysfunction of neuromuscular junctions (NMJs) of extraocular skeletal muscles and levator palpebral muscles in ocular MG, often impair vision sufficiently to interfere with work and quality of life. Whereas ocular symptoms are often the presenting symptoms of MG, they also tend to be the symptoms most refractory to treatment. Response to anticholinesterases is often incomplete,3 and pharmacological suppression of the NMJ immune attack or thymectomy is often required for resolution of symptoms.4-6 The judicious use of corticosteroids represents a key component of management of individual patients with ocular MG. A second consideration . . . [Full Text of this Article]
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Evidence report: The medical treatment of ocular myasthenia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
Benatar and Kaminski
Neurology 2007;68:2144-2149.
ABSTRACT
| FULL TEXT
Treatment of autoimmune myasthenia gravis
Bragdon et al.
Neurology 2004;63:1138-1139.
FULL TEXT
Development of Generalized Disease at 2 Years in Patients With Ocular Myasthenia Gravis
Kupersmith et al.
Arch Neurol 2003;60:243-248.
ABSTRACT
| FULL TEXT
|
